Immunome and Morphimmune’s Merger and Private Placement Investment

Mintz advised Immunome, and Cooley and Goodwin advised Morphimmune.Immunome (Nasdaq: IMNM) and Morphimmune announced that they have entered into a definitive merger agreement. The Boards of Directors…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here
Avatar

Author: Pietro Martinoia

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here